A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)

by Chataway Jeremy, Porter Bernadette, Riazi Afsane, Thompson Alan J, Hobart Jeremy C
Published 2011-09-01

The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?

by Bhatia Kailash P, Thompson Alan J, Warner Thomas T, Cano Stefan J, Fitzpatrick Ray, Hobart Jeremy C
Published 2008-08-01

The size of the treatment effect: do patients and proxies agree?

by Thompson Alan J, Klein Martin, Hobart Jeremy C, Kragt Jolijn J, van der Linden Femke AH, van der Ploeg Henk M, Polman Chris H, Uitdehaag Bernard MJ
Published 2009-03-01

Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years

by Thompson Alan J, Klein Martin, van Bon Margarethe, Kragt Jolijn J, van der Linden Femke AH, van der Ploeg Henk M, Polman Chris H, Uitdehaag Bernard MJ
Published 2008-02-01

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmen...

by Samson Rebecca S, Tozer Daniel J, Wheeler-Kingshott Claudia AM, Webber Daniel J, Barber Kelly, Richardson Karen, He Xiao-Ling, Crawley Charles, Scott Michael A, Patani Rickie, Kolappan Madhan, Connick Peter, Thomas David L, Du Ming-Qing, Luan Shi L, Michell Andrew W, Altmann Daniel R, Thompson Alan J, Miller David H, Compston Alastair, Chandran Siddharthan
Published 2011-03-01